RecruitingEarly Phase 1NCT05539833

KSH01-TCRT Solid Tumors

A Single-arm, Prospective Clinical Study of KSH01-TCR-T in the Treatment of Refractory/Recurrent Solid Tumors

Sponsor

TCRx Therapeutics Co.Ltd

Enrollment

50 participants

Start Date

Aug 19, 2022

Study Type

INTERVENTIONAL

Conditions

Refractory Solid Tumors Relapsed Solid Tumors TCR-T Cells

Summary

1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KSH01 injection for people with refractory solid tumors, relapsed solid tumors, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.